Influenza

Study of a Pandemic Influenza Vaccine in Elderly Participants

NCT00376402 | PHASE 2 | INTERVENTIONAL

The World Health Organisation has warned that an influenza pandemic is inevitable. The avian influenza H5N1 virus strain is one of the leading candidates to cause the next influenza pandemic. The elderly are likely to be a special target group for vaccination; therefore, this study will test the safety and immunogenicity of a H5N1 pandemic influenza vaccine in a healthy elderly population.

2 Sites

200 Participants

Recruiting

65 Years to 8 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Find closest sites:

SUBMIT

CMAX, a division of IDT Australia

Adelaide,South Australia,Australia,5000

Princess Margaret Hospital for Children

Perth,Western Australia,Australia,6840

Study Eligibility Criteria

Inclusion Criteria

* Healthy male and female participants

Exclusion Criteria

* History of clinically significant medical conditions
* History of Guillain-Barre syndrome or active neurological disease
* Resident of nursing home or long-term care facility

Additional Studies

Additional studies can be found at ClinicalTrials.gov